Sonoma Pharmaceuticals, Inc. (SNOA)

Sonoma Pharmaceuticals Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for Sonoma Pharmaceuticals.

Price Target: $0.00 (0.00%)

Analyst Consensus: n/a

Target	Low	Average	Median	High
Price	n/a	n/a	n/a	n/a
Change	n/a	n/a	n/a	n/a

Analyst Ratings

There are currently no analyst ratings available for Sonoma Pharmaceuticals.

Recommendation Trends

Rating	Jun '23	Jul '23	Aug '23	Sep '23
Strong Buy	0	0	0	0
Buy	0	0	0	0
Hold	1	1	1	0
Sell	0	0	0	0
Strong Sell	0	0	0	0
Total	1	1	1	0

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jeff Cohen Ladenburg Thalmann	Ladenburg Thalmann	Strong Buy Initiates $65	Strong Buy	Initiates	$65	+1,138.10%	Sep 5, 2023
Jason Kolbert Maxim Group	Maxim Group	Strong Buy → Hold Downgrades n/a	Strong Buy → Hold	Downgrades	n/a	n/a	Mar 6, 2018
Jason Kolbert Maxim Group	Maxim Group	Strong Buy Maintains $1,800 → $1,980	Strong Buy	Maintains	$1,800 → $1,980	+37,614.29%	Nov 10, 2017

More Analyst Ratings

Financial Forecast

Revenue This Year

17.57M

Increased by 23.00%

from 14.29M

Revenue Next Year

21.90M

Increased by 24.59%

from 17.57M

EPS This Year

-1.34

from -2.79

EPS Next Year

-0.46

from -1.34

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Mar 31, 2021	Mar 31, 2022	Mar 31, 2023	Mar 31, 2024	Mar 31, 2025	Mar 31, 2026	Mar 31, 2027
Revenue	18.63M	12.63M	13.27M	12.74M	14.29M	17.57M	21.90M
Revenue Growth	3.91%	-32.21%	5.10%	-4.05%	12.20%	23.00%	24.59%
EPS	-39.58	-38.34	-30.35	-10.63	-2.79	-1.34	-0.46
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	3	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	18.1M	22.5M
Avg	17.6M	21.9M
Low	16.9M	21.0M

Revenue Growth

Revenue Growth	2026	2027
High	26.6%	28.3%
Avg	23.0%	24.6%
Low	18.2%	19.7%

EPS Forecast

EPS	2026	2027
High	-1.38	-0.48
Avg	-1.34	-0.46
Low	-1.29	-0.44

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.